Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Operating Leases (2019 - 2025)

Historic Operating Leases for Voyager Therapeutics (VYGR) over the last 7 years, with Q3 2025 value amounting to $30.5 million.

  • Voyager Therapeutics' Operating Leases fell 2045.45% to $30.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.5 million, marking a year-over-year decrease of 2045.45%. This contributed to the annual value of $36.5 million for FY2024, which is 11351.94% up from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' Operating Leases is $30.5 million, which was down 2045.45% from $32.6 million recorded in Q2 2025.
  • Voyager Therapeutics' Operating Leases' 5-year high stood at $42.1 million during Q1 2021, with a 5-year trough of $17.1 million in Q4 2023.
  • For the 5-year period, Voyager Therapeutics' Operating Leases averaged around $31.0 million, with its median value being $34.6 million (2025).
  • As far as peak fluctuations go, Voyager Therapeutics' Operating Leases plummeted by 4745.45% in 2022, and later soared by 11512.73% in 2024.
  • Quarter analysis of 5 years shows Voyager Therapeutics' Operating Leases stood at $38.6 million in 2021, then plummeted by 47.44% to $20.3 million in 2022, then decreased by 15.77% to $17.1 million in 2023, then skyrocketed by 113.52% to $36.5 million in 2024, then fell by 16.38% to $30.5 million in 2025.
  • Its last three reported values are $30.5 million in Q3 2025, $32.6 million for Q2 2025, and $34.6 million during Q1 2025.